Palatin Technologies (PTN) Continues Upward On Female Viagra

Palatin Technologies, Inc. (NYSEMKT: PTN)

Palatin Technologies had a great day in the market today after the FDA approved a female sexual dysfunction product that’s being coined as “Female Viagra”; even though PTN didn’t create the medication. Today, those gains continue. So below, we’ll talk about the medication that was approved, how it affects Palatin Technologies, and what we can expect to see moving forward.

First Female Sexual Dysfunction Treatment Approved

Yesterday, we learned that Sprout Pharmaceuticals received approval for the first female sexual dysfunction medication in history. The medication is called Addyi. Sprout had to work incredibly hard to achieve approval of this medication. In all reality, they were declined twice before approval came. Addyi is designed to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women; .

How Does This Affect Palatin Technologies

Sprout is a Palatin Technologies competitor. So, how does Sprout getting approved for Addyi have any effect on Palatin Technologies? Well, PTN is in the process of producing their own treatment for female sexual dysfunction known as Bremelanotide. Bremelanotide is currently undergoing phase 3 testing; from which results will be announced in mid-2016. If everything goes well with the study, PTN will be submitting a NDA with the FDA for Bremelanotide as a treatment for hypoactive sexual desire disorder (HDD).

What We’re Seeing From The Stock Today

As I predicted yesterday, we’re starting to see more gains out of PTN today. Currently (11:44), the stock is trading at $1.04 per share after a gain of 7.22% so far.

What To Expect Moving Forward

Moving forward, I’m expecting to see a continuation of good news from PTN. Although the company is in clinical stages at the moment, I suspect that will change by 2017 as Bremelanotide edges toward approval. Also, there has been a stigma around the concept of a female sexual dysfunction medication. However, with the approval of Addyi, those who were skeptical about PTN’s ability to get Bremelanotide approved are no longer concerned. All in all, things look to be looking up for Palatin Technologies.

What Do You Think?

Where do you think PTN is headed and why? Let us know in the comments below!

Image Credit

Leave a Comment